Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy

Gynecol Oncol. 2024 Aug:187:113-119. doi: 10.1016/j.ygyno.2024.05.010. Epub 2024 May 17.

Abstract

Objective: The majority of high-grade serous carcinomas (HGSC) of the ovary, fallopian tube, and peritoneum arise from the precursor lesion called serous tubal intraepithelial carcinoma (STIC). It has been postulated that cells from STICs exfoliate into the peritoneal cavity and give rise to peritoneal HGSC several years later. While co-existent STICs and HGSCs have been reported to share similarities in their mutational profiles, clonal relationship between temporally distant STICs and HGSCs have been infrequently studied and the natural history of STICs remains poorly understood.

Methods: We performed focused searches in two national databases from the Netherlands and identified a series of BRCA1/2 germline pathogenic variant (GPV) carriers (n = 7) who had STIC, and no detectable invasive carcinoma, at the time of their risk-reducing salpingo-oophorectomy (RRSO), and later developed peritoneal HGSC. The clonal relationship between these STICs and HGSCs was investigated by comparing their genetic mutational profile by performing next-generation targeted sequencing.

Results: Identical pathogenic mutations and loss of heterozygosity of TP53 were identified in the STICs and HGSCs of five of the seven patients (71%), confirming the clonal relationship of the lesions. Median interval for developing HGSC after RRSO was 59 months (range: 24-118 months).

Conclusion: Our results indicate that cells from STIC can shed into the peritoneal cavity and give rise to HGSC after long lag periods in BRCA1/2 GPV carriers, and argues in favor of the hypothesis that STIC lesions may metastasize.

Keywords: BRCA1/2; Clonality; High-grade serous carcinoma; Next-generation sequencing; Serous tubal intra-epithelial carcinoma; TP53.

MeSH terms

  • Adult
  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Carcinoma in Situ / genetics
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / surgery
  • Cystadenocarcinoma, Serous* / genetics
  • Cystadenocarcinoma, Serous* / pathology
  • Cystadenocarcinoma, Serous* / prevention & control
  • Cystadenocarcinoma, Serous* / surgery
  • Fallopian Tube Neoplasms* / genetics
  • Fallopian Tube Neoplasms* / pathology
  • Fallopian Tube Neoplasms* / prevention & control
  • Fallopian Tube Neoplasms* / surgery
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / pathology
  • Ovarian Neoplasms* / prevention & control
  • Ovarian Neoplasms* / surgery
  • Peritoneal Neoplasms / genetics
  • Peritoneal Neoplasms / pathology
  • Salpingo-oophorectomy*

Substances

  • BRCA2 protein, human
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA1 Protein